Evidence map›Paper›PMID 31947516›Full record

ArticleJournal of clinical medicine2020

Pulmonary Arterial Hypertension Induces a Distinct Signature of Circulating Metabolites.

Ruslan Rafikov, Dawn K Coletta, Lawrence J Mandarino, Olga Rafikova

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Glucose-6-phosphate dehydrogenase deficiency contributes to metabolic abnormality and pulmonary hypertension.American journal of physiology. Lung cellular and molecular physiology · 2021
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ruslan RafikovDepartment of Medicine, Division of Endocrinology, University of Arizona College of Medicine, Tucson, AZ 85721, USA.
Dawn K ColettaDepartment of Medicine, Division of Endocrinology, University of Arizona College of Medicine, Tucson, AZ 85721, USA.
Lawrence J MandarinoDepartment of Medicine, Division of Endocrinology, University of Arizona College of Medicine, Tucson, AZ 85721, USA.
Olga RafikovaDepartment of Medicine, Division of Endocrinology, University of Arizona College of Medicine, Tucson, AZ 85721, USA.

Funding

Pulmonary Hypertension Breakthrough InitiativeR24HL123767 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI ALDRED, MICHEALA A, ERZURUM, SERPIL C. · 2014 to 2017
$10.1M
Anaplerotic reprogramming of endothelial cells in pulmonary hypertension.R01HL132918 · NHLBI · UNIVERSITY OF ARIZONA · PI RAFIKOV, RUSLAN · 2016 to 2025
$4.5M
HMGBG1 and Gender Difference in Pulmonary Arterial HypertensionR01HL133085 · NHLBI · UNIVERSITY OF ARIZONA · PI RAFIKOVA, OLGA · 2016 to 2020
$1.9M
NHLBI NIH HHS R01 HL132918NHLBI NIH HHS R01HL132918NHLBI NIH HHS R01 HL133085NHLBI NIH HHS R01HL133085NHLBI NIH HHS R24 HL123767NHLBI NIH HHS R24HL123767
6 · The paper itself

Abstract

Pulmonary arterial hypertension (PAH) is an incurable, progressive disorder, and the early diagnosis and treatment of PAH are associated with increased survival [...].

Indexed as

biomarkersdiabetesmetabolitespulmonary arterial hypertension

Identifiers

PMID31947516
PMCPMC7019706

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.